Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3671-3676

  Tonkinson, John L ^a   Worzalla, John F ^a   Teng, Chi Hse ^a   Mendelsohn, Laurane G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; GEMCITABINE; PEMETREXED;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL DEATH; CELL DIVISION; COLONIC NEOPLASMS; DEOXYCYTIDINE; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION;

EID: 0033179374     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Grindey, G. B., Moran, R. G., and Werkheiser, W. C. Approaches to the rational combination of antimetabolites for cancer chemotherapy. In: E. J. Ariens (ed.), Drug Design, pp. 169-249. New York: Academic Press, 1975.
2. Berenbaum, M. C. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin. Exp. Immunol. 28: 1-18, 1977.
3. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
4. Kisliuk, R. L., Thorndike, J., Gaumont, Y., Nair, M., G., Powers, J. F., and Piper, J. R. Synergistic growth inhibition by combination of antifolates. In: M. F. Picciano, E. L. R. Stokstad, and J. F. Gregory, III (eds.), Evaluation of Folate Metabolism in Health and Disease, pp. 79-89. New York: Alan R. Liss, Inc., 1990.
5. Prichard, M. N., and Shipman, C., Jr. A three dimensional model to analyze drug-drug interactions. Antiviral Res., 14: 181-206, 1990.
6. Jackson, R. C. Biochemical principles of drug interaction. In: R. C. Jackson (ed.), The Theoretical Foundations of Cancer Chemotherapy Introduced by Computer Models, pp. 342-379. New York: Academic Press, 1992.
7. Wampler, G. L., Carter, W. H., Jr., Campbell, E. D., and Keefe, P. A. Relationships between various uses of antineoplastic drug-interaction terms. Cancer Chemother. Pharmacol., 31: 111-117, 1992.
8. Shih, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., Andis, S. L., Bewley, J. R., Rayl, E. A., Moroson, B. A., Beardsley, G. P., Kohler, W., Ratnam, M., and Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res., 57: 1116-1123, 1997.
9. Tonkinson, J. L., Marder, P., Andis, S. L., Schultz, R. M., Gossett, L. S., Shih, C., and Mendelsohn, L. G. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol., 39: 521-531, 1997.
10. Hertel, L. W., Kroin, J. S., Misner, J. W., and Tustin, J. M. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleotides. J. Org. Chem., 53: 2406-2409, 1988.
11. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of the antitumor activity of a (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50: 4417-4422, 1990.
12. Carmichael, J., Fink, U., Russell, R. C., Spittle, M. F., Harris, A. L., Spiessi, G., and Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer, 73: 101-105, 1996.
13. Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
14. Burris, H., and Storniolo, A. M. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur. J. Cancer, 1: S18-S22, 1997.
15. Gatzemeier, U., Manegold, C., Eberhard, W., Wilke, H. J., Chomy, F., Chomy, P., Khayat, D., Blatter, J., Seeber, S., and Drings, P. A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Semin. Oncol., 24: S8-36-S8-38, 1997.
16. Halme, M., Jekunen, A., Tamminen, K., and Mattson, K. Phase II study of weekly gemcitabine in advanced non-small cell lung cancer. Respir. Med., 91: 423-426, 1997.
17. Prendiville, J., and O'Brien, M. Gemcitabine. Br. J. Hosp. Med., 57. 405-409, 1997.
18. Yokoyama, A., Nakai, Y., Yneda, S., Kurita, Y., and Niitani, H. Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study. Anticancer Drugs, 8: 574-581, 1997.
19. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
20. Huang, P., Chubb, S., Hertel., L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
21. Plunkett, W., Gandhi, V., Chubb, S., Nowak, B., Heinemann, V., Mineishi, S., Sen, A., Hertel., L. W., and Grindey, G. B. 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides, 8: 775-785, 1989.
22. Worzalla, J. F., Bewley, J. R., and Grindey, G. B. Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest. New Drugs, 8: 241-251, 1990.
23. Montgomery, D. C. Design and Analysis of Experiments, Ed. 2, p. 64. New York: John Wiley & Sons, 1984.
24. Kramer, C. Y. Extension of multiple range tests to group means with unequal number of replications. Biometrics, 12: 307-310, 1956.
25. Chen, V. J., Bewley, J. R., Andis, S. L., Schultz, R. M., Iversen, P. W., Shih, C., Mendelsohn, L. G., Seitz, D. E., and Tonkinson, J. L. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br. J. Cancer, 77: S3, 27-34, 1998.
26. Matsui, S., Arredondo, M. A., Wrzosek, C., and Rustum, Y. M. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res., 56: 4715-4723, 1996.
27. Weber, G., Ichikawa, S., Nagai, M., and Natsumeda, Y. Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Commun., 2: 129-133, 1990.
28. Pressacco, J., and Erlichman, C. Combination studies with 3′-azido-3′deoxy-thymidine (AZT) plus ICI D1694. Biochem. Pharmacol., 46: 1989-1997, 1993.
29. Pressacco, J., Hedley, D. W., and Erlichman, C. ICI D1694 and idoxuridine: a synergistic antitumor combination. Cancer Res., 54: 3772-3778, 1994.
30. Pressacco, J., Mitrovski, B., and Erlichman, C. Cytotoxic and biochemical implications of combining AZT and AG-331. Cancer Chemother. Pharmacol., 35: 387-390, 1995.
31. Yasuda, C., Kato, M., Kuroda, D., and Ohyanagi, H. Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3′-azido-3′-deoxymymidine for the gastric cancer cell line MKN28 in vivo. Jpn. J. Cancer Res., 88: 97-102, 1997.